Working, P.

ciprofloxacin pl cipro aeruginosa liposomes cipro treatment agents chemother concentration infection blood model efficacy agent pneumonia inoculation administration chemother liposomal antimicrob right lung ratio study bacteria dosage fluoroquinolone pneumoniae right tissue aeruginosa pneumonia survival effect antibiotic 160 mg /kg side effects ciprofloxacin concentrations pseudomona pseudomonas aeruginosa auc /mic ratio 20 mg /kg pharmacodynamic animal pharmacokinetic result pegylated liposomal ciprofloxacin aeruginosa pneumonia-septicemia toxicity interval number 40 mg /kg bakker-woudenberg antimicrobial patient 7 days culture klebsiella pneumoniae pneumonia table klebsiella 1998. serum 80 mg /kg particle size pegylated alza corporation antimicrobial treatment neutropenic rat model pneumonia-septicemia 3 days strain liposomal ciprofloxacin circulation 4 days aeruginosa infection placebo liposomes auc /mic ratios delivery intracellular lipid increase weight susceptibility